



PRESS RELEASE

Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.

Bengaluru, Karnataka, India. April- 17th, 2024

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialization of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.

Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.

Biomm is Brazil's first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments. The Company focuses on developing, manufacturing and commercializing complex biotech and biosimilar drug products at their state-of-the-art production facility in Nova Lima.

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said, *"Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the U.S. and Europe for Peptides. This is also in line with our growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products. We are confident that our collaboration with Biomm will provide patients in Brazil, who are living with diabetes, much needed access to advanced, high quality treatment options to help them manage the disease better."*

Heraldo Marchezini, Chief Executive Officer, Biomm, commented: *"Brazil is the fifth country in the world with the highest incidence of diabetes, having 16.8 million adults in the age group of 20 to 79 years with the disease, and an estimated 21.5 million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF). We have, therefore, prioritized strategic partnerships to expand the population's access to advanced treatments for this disease and enhance the quality of life for people"*.

The total addressable market opportunity of Semaglutide in Brazil is approximately US \$580 million as per the IQVIA MAT Q4 2023

~~~~~

**About Biocon Limited:** Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led, global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. [www.biocon.com](http://www.biocon.com)

**About Biomm:** Biomm's mission is to develop, produce, and market globally competitive biopharmaceuticals with quality and accessibility. The company's focus is on the development of affordable biological drugs for the treatment of chronic diseases in the country. With innovation in its DNA, the company is a pioneer in the biotechnological pharmaceutical sector in Brazil. It is headquartered and has a factory in Nova Lima (MG). It is listed on the stock exchange (B3:BIOM3). For more information, visit [www.biomm.com](http://www.biomm.com).

**Forward-Looking Statements: Biocon**

*This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.*

|                                                                                                                                                               |                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Media Relations</b><br>BIOCON LIMITED<br>Calvin Printer +91 70329 69537<br>Email: <a href="mailto:calvin.printer@biocon.com">calvin.printer@biocon.com</a> | <b>Investor Relations</b><br>BIOCON LIMITED<br>Saurabh Paliwal +91 95383 80801<br>Email: <a href="mailto:saurabh.paliwal@biocon.com">saurabh.paliwal@biocon.com</a> |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|